SYSTEMATIC REVIEW article
Front. Nutr.
Sec. Nutrition and Metabolism
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1644538
Therapeutic effects and safety of resveratrol for lung cancer: an updated preclinical systematic review and meta-analysis
Provisionally accepted
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Lung cancer (LC) is the most common cause of cancer-related death worldwide while there are limited treatment methods. Resveratrol (RESV), a natural food-derived compound, has attracted attention around the world for its anti-LC effects. However, little is known about the efficacy and safety of RESV for LC. Purpose: To provide preclinical evidence for the efficacy and safety of RESV for LC, and to find the optimal dose and duration. Methods: In-vivo studies of RESV against LC published before July 24, 2024 were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. CAMARADES checklist was used to assess study quality. Primary outcomes were tumor volume and tumor weight. Secondary outcomes included body weight, lung metastases number, and apoptotic cell proportion. Statistical analysis was performed using RevMan 5.3 and Stata 16.0. Dose-duration-effect model was conducted to determine the optimal dose and duration, and the toxicology of RESV was predicted through ProTox 3.0 platform. Results: Twenty-three studies involving 425 animals were included. The methodological quality of included studies was medium-to-low. RESV significantly reduced tumor volume, tumor weight and lung metastases number, and increased apoptotic cell proportion, while had no effect on body weight. High heterogeneity was observed, and subgroup analysis suggested that the heterogeneity was partly attributed to the dose of RESV. The optimal dose and duration of RESV were 30-100 mg/kg and 25-28 days. The median lethal dose of RESV was 1,560 mg/kg. Conclusions: RESV demonstrated a significant inhibitory effect on LC in-vivo. However, the lower research quality and high heterogeneity call for more high-quality preclinical studies to be conducted. Before achieving clinical translational research on RESV, the problem of low bioavailability of RESV needs to be solved.
Keywords: lung cancer, resveratrol, Preclinical evidence, Meta-analysis Abbreviations: B2D, twice every two days, BaP, benzo[a]pyrene, BBB , blood-brain barrier, CAFs, cancer-associated fibroblasts, CI, confidence interval
Received: 12 Jun 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Xiao, Wu, Li, You and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiang Xiao, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Fengming You, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Jing Guo, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.